The imbalance of vascular molecules in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 32, Issue 3, 2012, Pages 699-709

  Bell, Robert D ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

APOE4; blood brain barrier; cardiovascular; LRP1; MEOX2; MYOCD; neurovascular; RAGE; SRF

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CYCLOPHILIN A; GELATINASE B; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MYOCARDIN; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR FOXC2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN PERFUSION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE COURSE; GENE OVEREXPRESSION; GENETIC RISK; HEART OUTPUT; HOMOZYGOSITY; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

EID: 84872248887     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121060     Document Type: Review

References (130)

1. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-Brain barrier disorder in alzheimer's disease. Acta Neuropathol 118, 103-113.
2. de la Torre JC (2010) Vascular risk factor detection and control may prevent alzheimer's disease. Ageing Res Rev 9, 218-225.
3. de la Torre JC, Mussivand T (1993) Can disturbed brain microcirculation cause alzheimer's disease? Neurol Res 15, 146-153. (Pubitemid 23166998)
4. Zlokovic BV (2005) Neurovascular mechanisms of alzheimer's neurodegeneration. Trends Neurosci 28, 202208.
5. Zlokovic BV (2008) The blood-Brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
6. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
7. Iadecola C, Anrather J (2011) Stroke research at a crossroad: Asking the brain for directions. Nat Neurosci 14, 1363-1368.
8. Vangilder RL, Rosen CL, Barr TL, Huber JD (2011) Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Therap 130, 239-247.
9. Winkler EA, Bell RD, Zlokovic BV (2011) Central nervous system pericytes in health and disease. Nat Neurosci 14, 1398-1405.
10. Iadecola C, Nedergaard M (2007) Glial regulation of the cerebral microvasculature. Nat Neurosci 10, 1369-1376. (Pubitemid 350014688)
11. Mann GE, ZlokovicBV,Yudilevich DL (1985) Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: Kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim Biophys Acta 819, 241-248. (Pubitemid 16238675)
12. Zlokovic BV, Apuzzo ML (1997) Cellular and molecular neurosurgery: Pathways from concept to reality-part I: Target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery 40, 789-803; discussion 803-784.
13. Zlokovic BV, Begley DJ, Chain-Eliash DG (1985) Blood-Brain barrier permeability to leucine-enkephalin, D-Alanine2-D-Leucine5-enkephalin and their N-Terminal amino acid (tyrosine). Brain Res 336, 125-132. (Pubitemid 15013869)
14. Zlokovic BV, Segal MB, Begley DJ, Davson H, Rakic L (1985) Permeability of the blood-cerebrospinal fluid and blood-Brain barriers to thyrotropin-Releasing hormone. Brain Res 358, 191-199. (Pubitemid 16184089)
15. Zlokovic BV, Mackic JB, Djuricic B, Davson H (1989) Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-Brain barrier of an in situ perfused guinea-pig brain. J Neurochem 53, 1333-1340. (Pubitemid 19266997)
16. Zlokovic BV, Hyman S, McComb JG, Lipovac MN, Tang G, Davson H (1990) Kinetics of arginine-Vasopressin uptake at the blood-Brain barrier. Biochim Biophys Acta 1025, 191198.
17. Moskowitz MA, Lo EH, Iadecola C (2010) The science of stroke: Mechanisms in search of treatments. Neuron 67, 181198.
18. Guo S, LoEH(2009) Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke 40, S4-S7.
19. Zlokovic BV, Griffin JH (2011) Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci 34, 198-209.
20. Guo S, LoEH(2009) Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke 40, S4-S7.
21. Vangilder RL, Rosen CL, Barr TL, Huber JD (2011) Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ther 130, 239-247.
22. Boillee S,Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G,Kollias G, ClevelandDW(2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392. (Pubitemid 43839552)
23. Querfurth HW, LaFerla FM (2010) alzheimer's disease. N Engl J Med 362, 329-344.
24. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672. (Pubitemid 47283144)
25. Ittner LM, Gotz J (2011) Amyloid-Beta and tau-A toxic pas de deux in alzheimer's disease. Nat Rev Neurosci 12, 65-72.
26. Marchesi VT (2011) alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: Implications for early detection and therapy. FASEB J 25, 5-13.
27. Skoog I, Gustafson D (2006) Update on hypertension and alzheimer's disease. Neurol Res 28, 605-611.
28. Grammas P (2011) Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of alzheimer's disease. J Neuroinflammation 8, 26.
29. Breteler MM (2000) Vascular risk factors for alzheimer's disease: An epidemiologic perspective. Neurobiol Aging 21, 153-160. (Pubitemid 30387074)
30. Iadecola C, Gorelick PB (2003) Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34, 335-337. (Pubitemid 36206315)
31. Kalaria RN (2009) Neurodegenerative disease: Diabetes, microvascular pathology and alzheimer disease. Nat Rev Neurol 5, 305-306.
32. Kalaria RN (2000) The role of cerebral ischemia in alzheimer's disease. Neurobiol Aging 21, 321-330. (Pubitemid 30387091)
33. Shah NS,Vidal JS, Masaki K, Petrovitch H, RossGW, Tilley C, DeMattos RB, Tracy RP, White LR, Launer LJ (2012) Midlife blood pressure, plasma beta-Amyloid, and the risk for alzheimer disease: The Honolulu Asia Aging Study. Hypertension 59, 780-786.
34. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ (2000) Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging 21, 49-55. (Pubitemid 30224785)
35. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM (2007) Atherosclerosis and risk for dementia. Ann Neurol 61, 403-410. (Pubitemid 46878768)
36. Carnevale D, Lembo G (2011) 'Alzheimer-Like' pathology in a murine model of arterial hypertension. Biochem Soc Trans 39, 939-944.
37. Carnevale D, Mascio G, Ajmone-Cat MA, D'Andrea I, Cifelli G, Madonna M, Cocozza G, Frati A, Carullo P, Carnevale L, Alleva E, Branchi I, Lembo G, Minghetti L (2012) Role of neuroinflammation in hypertension-induced brain amyloid pathology. Neurobiol Aging 33, 205 e219-205 e229.
38. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G (2012) Hypertension induces brain beta-Amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60, 188-197.
39. Hardy JA, Higgins GA (1992) alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
40. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
41. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
42. Zlokovic B (1997) Can blood-Brain barrier play a role in the development of cerebral amyloidosis and alzheimer's disease pathology. Neurobiol Dis 4, 23-26.
43. Zlokovic BV (1996) Cerebrovascular transport of alzheimer's amyloid beta and apolipoproteins J and E: Possible anti-Amyloidogenic role of the blood-Brain barrier. Life Sci 59, 1483-1497. (Pubitemid 26358266)
44. Martel CL, Mackic JB, McComb JG, Ghiso J, Zlokovic BV (1996) Blood-Brain barrier uptake of the 40 and 42 amino acid sequences of circulating alzheimer's amyloid beta in guinea pigs. Neurosci Lett 206, 157-160. (Pubitemid 26096445)
45. Zlokovic BV,Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J (1996) Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with alzheimer disease amyloid beta at the blood-Brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93, 4229-4234.
46. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, Bading J, Frangione B, Zlokovic BV (1998) Cerebrovascular accumulation and increased blood-Brain barrier permeability to circulating alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 70, 210-215. (Pubitemid 28020845)
47. Mawuenyega KG, SigurdsonW, Ovod V, Munsell L, Kasten T, Morris JC,Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-Amyloid in alzheimer's disease. Science 330, 1774.
48. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV (2005) Role of the MEOX2 homeobox gene in neurovascular dysfunction in alzheimer disease. Nat Med 11, 959-965. (Pubitemid 41294441)
49. Gorski DH, Walsh K (2003) Control of vascular cell differentiation by homeobox transcription factors. Trends Cardiovasc Med 13, 213-220. (Pubitemid 36960167)
50. Bell RD,Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409-427.
51. Rovelet-Lecrux A, Legallic S, Wallon D, Flaman JM, Martinaud O, Bombois S, Rollin-Sillaire A, Michon A, Le Ber I, Pariente J, Puel M, Paquet C, Croisile B, Thomas-Anterion C, Vercelletto M, Levy R, Frebourg T, Hannequin D, CampionD(2011)Agenome-wide study reveals rare CNVs exclusive to extreme phenotypes of alzheimer disease. Eur J Hum Genet 20, 613-617.
52. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV (2009) SRF and myocardin regulate LRPmediated amyloid-Beta clearance in brain vascular cells. Nat Cell Biol 11, 143-153.
53. Chow N, Bell RD, Deane R, Streb JW, Chen J, Brooks A, Van Nostrand W, Miano JM, Zlokovic BV (2007) Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in alzheimer's phenotype. Proc Natl Acad Sci U S A 104, 823-828. (Pubitemid 46154695)
54. Mahley RW(1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
55. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein e and apolipoprotein e receptors: Normal biology and roles in alzheimer disease. Cold Spring Harb Perspect Med 2, a006312.
56. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in alzheimer's disease. Neuron 63, 287303.
57. Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in alzheimer's disease and other neurological disorders. Lancet Neurol 10, 241-252.
58. Mahley RW,Weisgraber KH, Huang Y (2009) Apolipoprotein E: Structure determines function, from atherosclerosis to alzheimer's disease to AIDS. J Lipid Res 50(Suppl), S183-S188.
59. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA (2007) A high-Density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset alzheimer's disease. J Clin Psychiatry 68, 613-618. (Pubitemid 46663046)
60. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset alzheimer disease. Nat Genet 7, 180-184. (Pubitemid 24174658)
61. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloid-Beta peptide clearance. Sci Transl Med 3, 89ra57.
62. Nathan BP, Jiang Y, Wong GK, Shen F, Brewer GJ, Struble RG (2002) Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-Density lipoprotein receptor-Related protein. Brain Res 928, 96-105. (Pubitemid 34159056)
63. Fagan AM, Bu G, Sun Y, Daugherty A, Holtzman DM (1996) Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-Related protein. J Biol Chem 271, 30121-30125. (Pubitemid 26389653)
64. Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T (2011) Blocking the apolipoprotein E/amyloid-Beta interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis 24, 269-285.
65. Bales KR (2010) Brain lipid metabolism, apolipoprotein E and the pathophysiology of alzheimer's disease. Neuropharmacology 59, 295-302.
66. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516.
67. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV (2008) apoE isoform-Specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118, 4002-4013.
68. Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, Abe J, Alexis JD, Sparks JD, Berk BC (2011) Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-Deficient mice. J Exp Med 208, 53-66.
69. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J, Illig KA, Berk BC (2009) Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 15, 649-656.
70. Satoh K, Nigro P, Zeidan A, Soe NN, Jaffre F, Oikawa M, O'Dell MR, Cui Z, Menon P, Lu Y, Mohan A, Yan C, Blaxall BC, Berk BC (2011) Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-Deficient mice. Arterioscler Thromb Vasc Biol 31, 1116-1123.
71. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA (2010) Low-Density lipoprotein receptor-Related protein1: A serial clearance homeostatic mechanism controlling alzheimer's amyloid beta-peptide elimination from the brain. J Neurochem 115, 1077-1089.
72. Bown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas AF, Gretarsdottir S, Badger SA, Bradley DT, Burnand K, Child AH, Clough RE, Cockerill G, Hafez H, Scott DJ, Futers S, Johnson A, Sohrabi S, Smith A, ThompsonMM,van Bockxmeer FM,Waltham M, Matthiasson SE, Thorleifsson G, Thorsteinsdottir U, Blankensteijn JD, Teijink JA, Wijmenga C, de Graaf J, Kiemeney LA, Assimes TL, McPherson R, Folkersen L, Franco-Cereceda A, Palmen J, Smith AJ, Sylvius N, Wild JB, Refstrup M, Edkins S, Gwilliam R, Hunt SE, Potter S, Lindholt JS, Frikke-Schmidt R, Tybjaerg-Hansen A, Hughes AE, Golledge J, Norman PE, van Rij A, Powell JT, Eriksson P, Stefansson K, Thompson JR, Humphries SE, Sayers RD, Deloukas P, Samani NJ (2011) Abdominal aortic aneurysm is associated with a variant in low-Density lipoprotein receptor-Related protein 1. Am J Hum Genet 89, 619-627.
73. Overton CD, Yancey PG, Major AS, Linton MF, Fazio S (2007) Deletion of macrophage LDL receptor-Related protein increases atherogenesis in the mouse. Circ Res 100, 670-677. (Pubitemid 46594881)
74. Boucher P, Gotthardt M, LiWP, Anderson RG, Herz J (2003) LRP: Role in vascular wall integrity and protection from atherosclerosis. Science 300, 329-332. (Pubitemid 36433724)
75. Yancey PG, DingY, FanD, Blakemore JL, ZhangY, Ding L, Zhang J, Linton MF, Fazio S (2011) Low-Density lipoprotein receptor-Related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: Evidence that the effects are not apolipoprotein E dependent. Circulation 124, 454-464.
76. Herz J, Bock HH (2002) Lipoprotein receptors in the nervous system. Annu Rev Biochem 71, 405-434. (Pubitemid 34800226)
77. Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D, Yepes M (2007) Tissue-Type plasminogen activator-mediated shedding of astrocytic low-Density lipoprotein receptor-Related protein increases the permeability of the neurovascular unit. Blood 109, 32703278.
78. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27, 909-918. (Pubitemid 46659038)
79. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ,Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344. (Pubitemid 39061126)
80. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of alzheimer's amyloid-Ss(1-40) peptide from brain by LDL receptorrelated protein-1 at the blood-Brain barrier. J Clin Invest 106, 1489-1499. (Pubitemid 32038587)
81. Urmoneit B, Prikulis I,Wihl G, D'Urso D, Frank R, Heeren J, Beisiegel U, Prior R (1997) Cerebrovascular smooth muscle cells internalize alzheimer amyloid beta protein via a lipoprotein pathway: Implications for cerebral amyloid angiopathy. Lab Invest 77, 157-166. (Pubitemid 27355912)
82. Wilhelmus MM, Otte-Holler I, van Triel JJ, Veerhuis R, Maat-Schieman ML, Bu G, de Waal RM, Verbeek MM(2007) Lipoprotein receptor-Related protein-1 mediates amyloid-Beta-mediated cell death of cerebrovascular cells. Am J Pathol 171, 1989-1999.
83. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid betaprotein clearance and alzheimer's disease susceptibility by the LDL receptor-Related protein pathway. J Clin Invest 106, 1159-1166.
84. Bading JR, Yamada S, Mackic JB, Kirkman L, Miller C, Calero M, Ghiso J, Frangione B, Zlokovic BV (2002) Brain clearance of alzheimer's amyloid-Beta40 in the squirrel monkey: A SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 10, 359-368. (Pubitemid 34746318)
85. Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-Beta protein in alzheimer's disease. Acta Neuropathol 112, 405-415. (Pubitemid 44469161)
86. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R (1997) Genetic association of the low-Density lipoprotein receptor-Related protein gene (LRP), an apolipoprotein E receptor, with late-onset alzheimer's disease. Neurology 49, 56-61. (Pubitemid 27328682)
87. Lambert JC, Wavrant-De Vrieze F, Amouyel P, ChartierHarlin MC (1998) Association at LRP gene locus with sporadic late-onset alzheimer's disease. Lancet 351, 17871788.
88. Wavrant-DeVrieze F, Lambert JC, Stas L, Crook R, Cottel D, Pasquier F, Frigard B, Lambrechts M, Thiry E, Amouyel P, Tur JP, Chartier-Harlin MC, Hardy J,Van Leuven F (1999) Association between coding variability in the LRP gene and the risk of late-onset alzheimer's disease. Hum Genet 104, 432-434. (Pubitemid 29286802)
89. Christoforidis M, Schober R, Krohn K (2005) Geneticmorphologic association study: Association between the low density lipoprotein-Receptor related protein (LRP) and cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 31, 11-19. (Pubitemid 40222821)
90. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, HamshereML,Pahwa JS, MoskvinaV,Dowzell K,Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, FoxN, Rossor M, Collinge J, MaierW, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with alzheimer's disease. Nat Genet 41, 1088-1093.
91. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with alzheimer's disease. Nat Genet 41, 1094-1099.
92. Sagare AP, Winkler EA, Bell RD, Deane R, Zlokovic BV (2011) From the liver to the blood-Brain barrier: An interconnected system regulating brain amyloid-Beta levels. J Neurosci Res 89, 967-968.
93. Sagare A, Deane R, Bell RD, Johnson B,HammK, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D,ComaM,Zhong Z, ZlokovicBV(2007) Clearance of amyloid-Beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031. (Pubitemid 47517512)
94. Berk BC (2007) Novel approaches to treat oxidative stress and cardiovascular diseases. Trans Am Clin Climatol Assoc 118, 209-214.
95. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV (2011) Impaired lipoprotein receptormediated peripheral binding of plasma amyloid-Beta is an early biomarker for mild cognitive impairment preceding alzheimer's disease. J Alzheimers Dis 24, 25-34.
96. Neeper M, Schmidt AM, Brett J, Yan SD,Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267, 14998-15004.
97. Deane R, DuYan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C,Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-Beta peptide transport across the blood-Brain barrier and accumulation in brain. Nat Med 9, 907-913. (Pubitemid 36889934)
98. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-Beta peptide neurotoxicity in alzheimer's disease. Nature 382, 685-691. (Pubitemid 26282167)
99. Yan SD,Yan SF, Chen X, Fu J, Chen M,Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, et al. (1995) Nonenzymatically glycated tau in alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1, 693-699.
100. Yan SF, Ramasamy R, SchmidtAM(2010) The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106, 842-853.
101. Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW (2008) Site-Specific blockade of RAGE-Vd prevents amyloid-Beta oligomer neurotoxicity. J Neurosci 28, 51495158.
102. Donahue J, Flaherty S, Johanson C, Duncan J, Silverberg G, Miller M, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa E (2006) RAGE, LRP-1, and amyloid-Beta protein in alzheimer's disease. Acta Neuropathol 112, 405-415. (Pubitemid 44469161)
103. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood-Brain barrier permeability precedes senile plaque formation in an alzheimer disease model. Microcirculation 10, 463-470. (Pubitemid 39004272)
104. Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, Zlokovic BV (2002) Circulating amyloid-Beta peptide crosses the blood-Brain barrier in aged monkeys and contributes to alzheimer's disease lesions. Vasc Pharmacol 38, 303-313. (Pubitemid 36398252)
105. Yan SF, Ramasamy R, SchmidtAM(2010) The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106, 842-853.
106. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-2835. (Pubitemid 35396983)
107. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83, 876-886. (Pubitemid 41598688)
108. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM (2009) The role of RAGE in amyloid-Beta peptide-mediated pathology in alzheimer's disease. Curr Opin Invest Drugs 10, 672-680.
109. Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalra VK (2000) betaamyloidinduced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol 279, C1772-C1781.
110. Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, Stopa EG (2008) Hippocampal RAGE immunoreactivity in early and advanced alzheimer's disease. Brain Res 1230, 273-280.
111. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, Larue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV (2012) A multimodal RAGE-Specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of alzheimer disease. J Clin Invest 122, 1377-1392.
112. Webster SJ, Mruthinti S, Hill WD, Buccafusco JJ, Terry AV Jr (2012) An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for alzheimer's disease. Neuromolecular Med 14, 119-130.
113. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S (1999) Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 131, 363-375. (Pubitemid 29424631)
114. Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: Evidence on causality from a metaanalysis. BMJ 325, 1202.
115. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and alzheimer's disease. N Engl J Med 346, 476-483. (Pubitemid 34441738)
116. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: A metaanalysis. JAMA 288, 2015-2022.
117. Chen C, Halkos ME, Surowiec SM, Conklin BS, Lin PH, Lumsden AB (2000) Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg Res 88, 26-33. (Pubitemid 30046535)
118. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP (2003) Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. Circulation 108, 933-938. (Pubitemid 37048221)
119. Bilsborough W, Green DJ, Mamotte CD, van Bockxmeer FM, O'Driscoll GJ, Taylor RR (2003) Endothelial nitric oxide synthase gene polymorphism, homocysteine, cholesterol and vascular endothelial function. Atherosclerosis 169, 131-138. (Pubitemid 36830931)
120. Pruefer D, Scalia R, Lefer AM (1999) Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide. Gen Pharmacol 33, 487-498. (Pubitemid 30047154)
121. Kamath AF, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, Wagner DD (2006) Elevated levels of homocysteine compromise blood-Brain barrier integrity in mice. Blood 107, 591-593. (Pubitemid 43090794)
122. Dayal S, Arning E, Bottiglieri T, Boger RH, Sigmund CD, Faraci FM, Lentz SR (2004) Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke 35, 1957-1962. (Pubitemid 38971883)
123. Phillips A, Shaper AG, Whincup PH (1989) Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet 2, 1434-1436. (Pubitemid 20012066)
124. Gillum RF (2000) Assessment of serum albumin concentration as a risk factor for stroke and coronary disease in African Americans and whites. J Natl Med Assoc 92, 3-9.
125. Schalk BW, Visser M, Bremmer MA, Penninx BW, Bouter LM, Deeg DJ (2006) Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam. Am J Epidemiol 164, 969977.
126. Bohrmann B, Tjernberg L, Kuner P, Poli S, LevetTrafit B, Naslund J, Richards G, Huber W, Dobeli H, Nordstedt C (1999) Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-Amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 274, 1599015995.
127. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916-32922. (Pubitemid 27008725)
128. Prajapati KD, Sharma SS, Roy N (2011) Current perspectives on potential role of albumin in neuroprotection. Rev Neurosci 22, 355-363.
129. Ginsberg MD (2008) Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology 55, 363-389.
130. Nimmagadda A, Park HP, Prado R, Ginsberg MD (2008) Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: A twophoton laser-Scanning microscopy study. Stroke 39, 198204.